ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors

ClinicalTrials.gov ID: NCT05662852

Public ClinicalTrials.gov record NCT05662852. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Clinical Study of the Safety and Antibody Responses of Plasma Donors Vaccinated With a Licensed Tdap Vaccine for a Hyperimmunization Program

Study identification

NCT ID
NCT05662852
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
ABO Holdings, Inc.
Industry
Enrollment
100 participants

Conditions and interventions

Interventions

  • Tdap Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 63 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 4, 2023
Primary completion
May 11, 2025
Completion
May 11, 2025
Last update posted
Jun 26, 2025

2023 – 2025

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
ABO Plasma Glassboro New Jersey 08028

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05662852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 26, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05662852 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →